Section of Plastic Surgery, Department of Surgery, University of Michigan, Ann Arbor.
Center for Statistical Consultation and Research, University of Michigan, Ann Arbor.
JAMA Surg. 2018 Oct 1;153(10):901-908. doi: 10.1001/jamasurg.2018.1687.
In breast reconstruction, it is critical for patients and surgeons to have comprehensive information on the relative risks of the available options. However, previous studies that evaluated complications were limited by single-center designs, inadequate follow-up, and confounding.
To assess 2-year complication rates across common techniques for postmastectomy reconstruction in a multicenter patient population.
DESIGN, SETTING, AND PARTICIPANTS: This longitudinal, multicenter, prospective cohort study conducted from February 1, 2012, through July 31, 2015, took place at the 11 study sites associated with the Mastectomy Reconstruction Outcomes Consortium study. Eligible patients included women 18 years and older presenting for first-time breast reconstruction with at least 2 years of follow-up. Procedures evaluated included direct-to-implant (DTI) technique, expander-implant (EI) technique, latissimus dorsi (LD) flap, pedicled transverse rectus abdominis myocutaneous (pTRAM) flap, free transverse rectus abdominis myocutaneous (fTRAM) flap, deep inferior epigastric perforator (DIEP) flap, and superficial inferior epigastric artery (SIEA) flap.
Postmastectomy breast reconstruction.
Development of complications, reoperative complications, and wound infections during 2-year follow-up. Mixed-effects logistic regression analysis controlled for variability among centers and for demographic and clinical variables.
A total of 2343 patients (mean [SD] age, 49.5 [10.1] years; mean [SD] body mass index, 26.6 [5.7]) met the inclusion criteria. A total of 1525 patients (65.1%) underwent EI reconstruction, with 112 (4.8%) receiving DTI reconstruction, 85 (3.6%) pTRAM flaps, 95 (4.1%) fTRAM flaps, 390 (16.6%) DIEP flaps, 71 (3.0%) LD flaps, and 65 (2.8%) SIEA flaps. Overall, complications were noted in 771 (32.9%), with reoperative complications in 453 (19.3%) and wound infections in 230 (9.8%). Two years postoperatively, patients undergoing any autologous reconstruction type had significantly higher odds of developing any complication compared with those undergoing EI reconstruction (pTRAM flap: odds ratio [OR], 1.91; 95% CI, 1.10-3.31; P = .02; fTRAM flap: OR, 2.05; 95% CI, 1.24-3.40; P = .005; DIEP flap: OR, 1.97; 95% CI, 1.41-2.76; P < .001; LD flaps: OR, 1.87; 95% CI, 1.03-3.40; P = .04; SIEA flap: OR, 4.71; 95% CI, 2.32-9.54; P < .001). With the exception of LD flap reconstructions, all flap procedures were associated with higher odds of reoperative complications (pTRAM flap: OR, 2.48; 95% CI, 1.33-4.64; P = .005; fTRAM flap: OR, 3.02; 95% CI, 1.73-5.29; P < .001; DIEP flap: OR, 2.76; 95% CI, 1.87-4.07; P < .001; SIEA flap: OR, 2.62; 95% CI, 1.24-5.53; P = .01) compared with EI techniques. Of the autologous reconstructions, only patients undergoing DIEP flaps had significantly lower odds of infection compared with those undergoing EI procedures (OR, 0.45; 95% CI, 0.25-0.29; P = .006). However, DTI and EI procedures had higher failure rates (EI and DTI techniques, 7.1%; pTRAM flap, 1.2%; fTRAM flap, 2.1%; DIEP flap, 1.3%; LD flap, 2.8%; and SIEA flap, 0%; P < .001).
Significant differences were noted across reconstructive procedure types for overall and reoperative complications, which is critically important information for women and surgeons making breast reconstruction decisions.
重要性:在乳房重建中,患者和外科医生全面了解可用选择的相对风险至关重要。然而,以前评估并发症的研究受到单中心设计、随访不足和混杂因素的限制。
目的:评估多中心患者人群中常见乳房再造术后技术的 2 年并发症发生率。
设计、地点和参与者:这项从 2012 年 2 月 1 日至 2015 年 7 月 31 日进行的、为期 2 年的、多中心、前瞻性队列研究,在与乳房切除术重建结果联合会研究相关的 11 个研究地点进行。符合条件的患者包括年龄在 18 岁及以上、接受首次乳房重建且随访至少 2 年的女性。评估的手术包括直接置管(DTI)技术、扩张器-植入物(EI)技术、背阔肌(LD)皮瓣、带蒂横直腹肌皮瓣(pTRAM)皮瓣、游离横直腹肌皮瓣(fTRAM)皮瓣、腹壁下动脉穿支皮瓣(DIEP)和腹壁浅动脉皮瓣(SIEA)。
干预措施:乳房切除术乳房重建。
主要结果和测量指标:2 年随访期间的并发症、再次手术并发症和伤口感染的发生情况。混合效应逻辑回归分析控制了中心间的变异性以及人口统计学和临床变量。
结果:共有 2343 名患者(平均[标准差]年龄,49.5[10.1]岁;平均[标准差]体重指数,26.6[5.7])符合纳入标准。共有 1525 名患者接受 EI 重建,其中 112 名(4.8%)接受 DTI 重建,85 名(3.6%)接受 pTRAM 皮瓣,95 名(4.1%)接受 fTRAM 皮瓣,390 名(16.6%)接受 DIEP 皮瓣,71 名(3.0%)接受 LD 皮瓣,65 名(2.8%)接受 SIEA 皮瓣。总体而言,771 名(32.9%)患者发生并发症,其中 453 名(19.3%)患者发生再次手术并发症,230 名(9.8%)患者发生伤口感染。术后 2 年,与接受 EI 重建的患者相比,接受任何自体重建类型的患者发生任何并发症的几率显著更高(pTRAM 皮瓣:比值比[OR],1.91;95%置信区间[CI],1.10-3.31;P = .02;fTRAM 皮瓣:OR,2.05;95% CI,1.24-3.40;P = .005;DIEP 皮瓣:OR,1.97;95% CI,1.41-2.76;P < .001;LD 皮瓣:OR,1.87;95% CI,1.03-3.40;P = .04;SIEA 皮瓣:OR,4.71;95% CI,2.32-9.54;P < .001)。除 LD 皮瓣重建外,所有皮瓣手术与更高的再次手术并发症几率相关(pTRAM 皮瓣:OR,2.48;95% CI,1.33-4.64;P = .005;fTRAM 皮瓣:OR,3.02;95% CI,1.73-5.29;P < .001;DIEP 皮瓣:OR,2.76;95% CI,1.87-4.07;P < .001;SIEA 皮瓣:OR,2.62;95% CI,1.24-5.53;P = .01)与 EI 技术相比。在自体重建中,只有接受 DIEP 皮瓣的患者与接受 EI 手术的患者相比,感染的几率显著降低(OR,0.45;95% CI,0.25-0.29;P = .006)。然而,DTI 和 EI 手术的失败率更高(EI 和 DTI 技术,7.1%;pTRAM 皮瓣,1.2%;fTRAM 皮瓣,2.1%;DIEP 皮瓣,1.3%;LD 皮瓣,2.8%;SIEA 皮瓣,0%;P < .001)。
结论和相关性:不同重建手术类型在总体和再次手术并发症方面存在显著差异,这对女性和进行乳房重建决策的外科医生来说是非常重要的信息。